ERBB2 and breast carcinoma: Efforts are underway to address these resistance mechanisms, with some research focusing on the DNA repair pathway as a therapeutic target to synergize with ADCs, such as trastuzumab deruxtecan, in resistant HER2-overexpressing breast cancer [11].